Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen

Analysts call Intercept sell-off overblown in wake of EASL presentation of fuller Phase III data for OCA in NASH. But while depth is added to efficacy argument, pruritus concerns possibly worsen.